Imovax Polio

Poliovirus, the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular, subcutaneous use. It prevents poliomyelitis caused by poliovirus types 1, 2, and 3 in individuals at risk.

GNH USA supplies Imovax Polio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imovax Polio is used to induce immunity against poliovirus infection, thereby preventing poliomyelitis. - Poliomyelitis prevention: provides active immunity to protect against disease caused by poliovirus types 1, 2, and 3. - Travel protection: administered before travel to regions where polio remains endemic or where outbreaks occur. - Outbreak control: employed in mass vaccination campaigns to halt community transmission of poliovirus.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema and edema. - Low‑grade fever: transient elevation of body temperature. - Headache or malaise: general feeling of discomfort.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Guillain‑Barré syndrome: rare autoimmune neuropathy. - Seizures or encephalitis: extremely uncommon neurologic events.

Imovax Polio should be administered with consideration of the following precautions. - Allergy assessment: avoid if the patient has a known hypersensitivity to any vaccine component. - Immunocompromised patients: evaluate risk; vaccine is inactivated but immune response may be reduced. - Pregnancy: consult a healthcare provider; limited safety data are available. - Concurrent vaccines: may be given with other vaccines according to recommended schedules. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents; consider the following. Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks. - Immunoglobulin therapy: may diminish vaccine response; avoid within 2 weeks of vaccination. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may mask fever, monitor for underlying reactions. - Immunosuppressive drugs: may reduce antibody production, monitor immune response. - Blood products: may interfere with immunogenicity, assess timing relative to vaccination.